Xenova acquires Cantab in stock swap
Executive Summary
To create a European biopharmaceutical company focused primarily on therapeutics for cancer, Xenova (cancer drugs) will acquire vaccines and immunotherapeutics developer Cantab Pharmaceuticals in a stock swap that values the combined company at an estimated $179mm (UK124mm).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice